GVHD characteristics at treatment
. | Classic n = 1245 . | Late n = 193 . | P value . |
---|---|---|---|
GVHD grades II-IV | |||
1 | 401 (32.2) | 34 (17.6) | < .001 |
2-4 | 844 (67.8) | 159 (82.4) | |
GVHD grades III-IV | |||
1-2 | 1025 (82.3) | 123 (63.7) | < .001 |
3-4 | 220 (17.7) | 70 (36.3) | |
Minnesota risk | |||
Standard | 1058 (85.0) | 135 (69.9) | < .001 |
High | 187 (15.0) | 58 (30.1) | |
Skin stage II-IV | |||
0-1 | 656 (52.7) | 107 (55.4) | .486 |
2-4 | 589 (47.3) | 86 (44.6) | |
Lower gastrointestinal stage II-IV | |||
0-1 | 1056 (84.8) | 130 (67.4) | < .001 |
2-4 | 189 (15.2) | 63 (32.6) | |
Liver gastrointestinal stage II-IV | |||
0-1 | 1211 (97.3) | 183 (94.8) | .073 |
2-4 | 34 (2.7) | 10 (5.2) | |
Upper gastrointestinal stage | |||
0 | 868 (69.7) | 124 (64.2) | .133 |
1 | 377 (30.3) | 69 (35.8) | |
Initial corticosteroid dose (median methylprednisolone [mg/kg], range) | 0.91 (0.09-10.72) | 0.83 (0.16-2.37) | .713 |
Use of other agents in addition to systemic steroids | 102 (8.2) | 15 (7.8) | 1 |
Median days of initial treatment (range) | 30 (5-99) | 151 (102-330) | |
GVHD grades | |||
1 | 401 (32.2) | 34 (17.6) | < .001 |
2 | 624 (50.1) | 89 (46.1) | |
3 | 172 (13.8) | 59 (30.6) | |
4 | 48 (3.9) | 11 (5.7) | |
Skin stage | |||
0 | 407 (32.7) | 85 (44.0) | < .001 |
1 | 249 (20.0) | 22 (11.4) | |
2 | 339 (27.2) | 36 (18.7) | |
3 | 241 (19.4) | 50 (25.9) | |
4 | 9 (0.7) | 0 (0.0) | |
Lower gastrointestinal stage | |||
0 | 842 (67.6) | 98 (50.8) | < .001 |
1 | 214 (17.2) | 32 (16.6) | |
2 | 92 (7.4) | 29 (15.0) | |
3 | 62 (5.0) | 23 (11.9) | |
4 | 35 (2.8) | 11 (5.7) | |
Liver stage | |||
0 | 1195 (96.0) | 178 (92.2) | .090 |
1 | 16 (1.3) | 5 (2.6) | |
2 | 20 (1.6) | 5 (2.6) | |
3 | 9 (0.7) | 4 (2.1) | |
4 | 5 (0.4) | 1 (0.5) |
. | Classic n = 1245 . | Late n = 193 . | P value . |
---|---|---|---|
GVHD grades II-IV | |||
1 | 401 (32.2) | 34 (17.6) | < .001 |
2-4 | 844 (67.8) | 159 (82.4) | |
GVHD grades III-IV | |||
1-2 | 1025 (82.3) | 123 (63.7) | < .001 |
3-4 | 220 (17.7) | 70 (36.3) | |
Minnesota risk | |||
Standard | 1058 (85.0) | 135 (69.9) | < .001 |
High | 187 (15.0) | 58 (30.1) | |
Skin stage II-IV | |||
0-1 | 656 (52.7) | 107 (55.4) | .486 |
2-4 | 589 (47.3) | 86 (44.6) | |
Lower gastrointestinal stage II-IV | |||
0-1 | 1056 (84.8) | 130 (67.4) | < .001 |
2-4 | 189 (15.2) | 63 (32.6) | |
Liver gastrointestinal stage II-IV | |||
0-1 | 1211 (97.3) | 183 (94.8) | .073 |
2-4 | 34 (2.7) | 10 (5.2) | |
Upper gastrointestinal stage | |||
0 | 868 (69.7) | 124 (64.2) | .133 |
1 | 377 (30.3) | 69 (35.8) | |
Initial corticosteroid dose (median methylprednisolone [mg/kg], range) | 0.91 (0.09-10.72) | 0.83 (0.16-2.37) | .713 |
Use of other agents in addition to systemic steroids | 102 (8.2) | 15 (7.8) | 1 |
Median days of initial treatment (range) | 30 (5-99) | 151 (102-330) | |
GVHD grades | |||
1 | 401 (32.2) | 34 (17.6) | < .001 |
2 | 624 (50.1) | 89 (46.1) | |
3 | 172 (13.8) | 59 (30.6) | |
4 | 48 (3.9) | 11 (5.7) | |
Skin stage | |||
0 | 407 (32.7) | 85 (44.0) | < .001 |
1 | 249 (20.0) | 22 (11.4) | |
2 | 339 (27.2) | 36 (18.7) | |
3 | 241 (19.4) | 50 (25.9) | |
4 | 9 (0.7) | 0 (0.0) | |
Lower gastrointestinal stage | |||
0 | 842 (67.6) | 98 (50.8) | < .001 |
1 | 214 (17.2) | 32 (16.6) | |
2 | 92 (7.4) | 29 (15.0) | |
3 | 62 (5.0) | 23 (11.9) | |
4 | 35 (2.8) | 11 (5.7) | |
Liver stage | |||
0 | 1195 (96.0) | 178 (92.2) | .090 |
1 | 16 (1.3) | 5 (2.6) | |
2 | 20 (1.6) | 5 (2.6) | |
3 | 9 (0.7) | 4 (2.1) | |
4 | 5 (0.4) | 1 (0.5) |